Important: Please read all instructions below before completing FIS 2288.

Section 2212c of Public Act 218 of 1956, MCL 500.2212c, requires the use of a standard prior authorization form when a policy, certificate or contract requires prior authorization for prescription drug benefits.

A standard form, FIS 2288, is being made available by the Department of Insurance and Financial Services to simplify exchanges of information between prescribers and health insurers as part of the process of requesting prescription drug prior authorization. This form will be updated periodically and the form number and most recent revision date are displayed in the top left-hand corner.

- This form is made available for use by prescribers to initiate a prior authorization request with the health insurer.
- Prior authorization requests are defined as requests for pre-approval from an insurer for specified medications or quantities of medications before they are dispensed.
- “Prescriber” means the term as defined in section 17708 of the Public Health Code, 1978 PA 368, MCL 333.17708.
- “Prescription drug” means the term as defined in section 17708 of the Public Health Code, 1978 PA 368, MCL 333.17708.
- Pursuant to MCL 500.2212c, prescribers and insurers must comply with required timeframes pertaining to the processing of a prior authorization request. Insurers may request additional information or clarification needed to process a prior authorization request.
- The prior authorization is considered granted if the insurer fails to grant the request, deny the request, or require additional information of the prescriber within 72 hours after the date and time of submission of an expedited prior authorization request or within 15 days after the date and time of submission of a standard prior authorization request. If additional information is requested by an insurer, a prior authorization request is considered to have been granted by the insurer if the insurer fails to grant the request, deny the request, or otherwise respond to the request of the prescriber within 72 hours after the date and time of submission of the additional information for an expedited prior authorization request; or within 15 days after the date and time of submission of the additional information for standard prior authorization request.
- The prior authorization is considered void if the prescriber fails to submit the additional information within 5 days after the date and time of the original submission of a properly completed expedited prior authorization request or within 21 days after the date and time of the original submission of a properly completed standard prior authorization request.
- In order to designate a prior authorization request for expedited review, a prescriber must certify that applying the 15-day standard review period may seriously jeopardize the life and health of the patient or the patient’s ability to regain maximum function.

PRESCRIBERS PLEASE SUBMIT THIS FORM TO THE PATIENT’S HEALTH PLAN ONLY. Please do not send to the department.

Only provide the physician’s direct contact number and initials if you are requesting an Expedited Review Request.
Michigan Prior Authorization
Request Form for Prescription Drugs

(PRESCRIBERS SUBMIT THIS FORM TO THE PATIENT’S HEALTH PLAN)

| □ Standard Review Request |
| □ Expedited Review Request: I hereby certify that a standard review period may seriously jeopardize the life or health of the patient or the patient’s ability to regain maximum function. Physician’s Direct Contact Phone Number ( ) ______-_________ Initials: _________________ |

A) Reason for Request

□ Initial Authorization Request  □ Renewal Request  □ DAW

B) Patient Demographics

Is patient hospitalized:  □ Yes  □ No

Patient Name: ____________________________________________  DOB: _________________

Patient Health Plan ID: ________________________________________________________________

□ Male  □ Female

C) Pharmacy Insurance Plan

□ Priority  □ Magellan  □ Blue Cross Blue Shield of Michigan  □ HAP  □ Prescription Drug Plan

□ Total Health Care  □ Blue Care Network  □ HealthPlus of Michigan  □ Meridian Health Plan

D) Prescriber Information

Prescriber Name: ________________________  NPI: _________________  Specialty: ______________

DEA (required for controlled substance requests only): _____________________

Contact Name: __________________ Contact Phone: ______________ Contact Fax: _______________

Health Plan Provider ID (if accessible): __________________________________________________

E) Pharmacy Information (optional)

Pharmacy Name____________________________ Pharmacy Telephone_________________________

F) Requested Prescription Drug Information

Drug Name: _____________________________________________________  Strength: __________

Dosing Schedule: __________________________________________  Duration: _________________

Diagnosis (specific) with ICD#: __________________________________________________________

Place of infusion / injection (if applicable): _________________________________________________

Facility Provider ID / NPI: ______________________________________________________________

Has the patient already started the medication? _______ Yes _______No  If so, when? ___________
G) Rationale for Prior Authorization (e.g., information such as history of present illness, past medical history, current medications, etc.; you may also attach chart notes to support your request if you believe they will assist with the review process)

____________________________________________________________________________________
____________________________________________________________________________________
____________________________________________________________________________________

H) Failed/Contraindicated Therapies

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Strength</th>
<th>Dosing Schedule</th>
<th>Duration</th>
<th>Adverse Event/Specific Failure</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

I) Other Pertinent Information (Optional - to be filled out if other information is necessary such as relevant diagnostic labs, measures of response to treatment, etc.) Please refer to plan’s website for additional information that may be necessary for review. Please note that sending this form with insufficient clinical information may result in extended review period or adverse determination.

____________________________________________________________________________________
____________________________________________________________________________________
____________________________________________________________________________________

I represent to the best of my knowledge and belief that the information provided is true, complete and fully disclosed. A person may be committing insurance fraud if false or deceptive information with the intent to defraud is provided.

Physician’s Name: ____________________________________________________________

Physician’s Signature: _________________________________________________________

Date: ____________

PA 218 of 1956 as amended requires the use of a standard prior authorization form by prescribers when a patient’s health plan requires prior authorization for prescription drug benefits.

*For Health Plan Use Only*

<table>
<thead>
<tr>
<th>Request Date:</th>
<th>LOB:</th>
<th>Approved:</th>
<th>Denied:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Approved By:</td>
<td>Denied By:</td>
</tr>
<tr>
<td>Effective Date:</td>
<td>Reason for Denial:</td>
<td>Additional Comments:</td>
<td></td>
</tr>
</tbody>
</table>
UNIVERSITY OF MICHIGAN – Dupilumab (Dupixent)

Some of the information needed to make a determination for coverage is not specifically requested on the Michigan Prior Authorization Request Form for Prescription Drugs. To avoid delays in reviewing your request, please make sure to include all of the following information.

Please answer the following questions for your patient:

<table>
<thead>
<tr>
<th>Question</th>
<th>Y</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Does your patient have one of the following diagnoses? Please indicate which, or clarify below.</td>
<td>Y</td>
<td>N</td>
</tr>
<tr>
<td>A. Moderate-to-severe Atopic Dermatitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B. Severe Asthma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C. Oral Corticosteroid (OCS) Dependent Asthma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D. Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>E. Other: __________________________</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2. Is the prescribing provider a dermatologist, immunologist, or asthma specialist?  

For the treatment of Moderate-to-Severe Atopic Dermatitis:

<table>
<thead>
<tr>
<th>Measure of Disease Activity</th>
<th>Baseline</th>
<th>Current (for continuation)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date Assessed: ___________</td>
<td>Date Assessed: ___________</td>
<td></td>
</tr>
<tr>
<td>Body surface area (BSA) involvement (0-100%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eczema Area and Severity Index (EASI) Score (0-72)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physician Global Assessment (PGA) Score (0-5)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2. Has your patient tried and failed any of the following therapeutic categories? Please indicate which categories and product(s) your patient has tried and failed below.

<table>
<thead>
<tr>
<th>Category</th>
<th>Y</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. High-potency topical corticosteroids</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B. Topical calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C. Phototherapy Ultraviolet Light A (PUVA)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D. Ultraviolet Light B (UVB)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>E. Topical PDE-4 inhibitors (e.g., crisaborole)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
For the treatment of Eosinophilic Asthma:

1. Does your patient currently use any of the following therapeutic products for the treatment of severe asthma? Please indicate which, if any:
   - A. High dose inhaled corticosteroid (ICS)
   - B. Long acting beta-2 agonist (LABA)
   - C. Long acting muscarinic antagonist (LAMA)

2. Has your patient had a blood eosinophil count greater than or equal to 300 cells/mcl measured within the preceding six months?
   - Y N
   If yes, please include lab results with this request.

3. For continuation requests, has your patient experienced a decrease in the frequency of exacerbations and improvement in symptoms while receiving dupilumab?
   - Y N

For the treatment of OCS-Dependent Asthma:

1. Does your patient currently require daily oral corticosteroid use for treatment of their severe asthma?
   - Y N

2. Does your patient currently use a high-dose inhaled corticosteroid product for treatment of their severe asthma?
   - Y N

3. Does your patient currently use either of the following therapeutic agents for the treatment of severe asthma?
   - A. Long acting beta-2 agonist (LABA)
   - B. Long acting muscarinic antagonist (LAMA)

4. For continuation requests, has your patient decreased their dose of oral corticosteroids by at least 50% since starting dupilumab therapy?
   - Y N

5. For continuation requests, has your patient experienced a decrease in the frequency of exacerbations and improvement in symptoms AND decreased their dose of oral corticosteroid by any amount since starting dupilumab?
   - Y N

For the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP):

1. Has your patient tried and failed each of the following for their CRSwNP?
   - A. Intranasal corticosteroids
   - B. Surgical intervention
   - C. Oral corticosteroids

   Note: Previous trial and failure of the listed alternatives must be verifiable through medical records or pharmacy claims. Failure to include supporting documentation may result in coverage delays or adverse coverage determinations.

2. For continuation requests, does your patient continue to experience benefit from therapy with dupilumab for CRSwNP?
   - Y N

Revised August 9, 2019